Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H24N2O4 |
| Molecular Weight | 368.4263 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C3=C2C=CC(=O)N3)C=C1
InChI
InChIKey=IHOXNOQMRZISPV-YJYMSZOUSA-N
InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1
| Molecular Formula | C21H24N2O4 |
| Molecular Weight | 368.4263 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Carmoterol is a long-acting β2-adrenoceptor agonist with a rapid onset of action and potent bronchodilating activity. Carmoterol has a similar onset of action compared to salbutamol and formoterol, and a faster onset of action compared to salmeterol. Furthermore, the duration of tracheal smooth muscle relaxation is longer for carmoterol compared to both formoterol and salmeterol. In asthmatic patients, the PK of carmoterol is proportional to the dose, and nonlinear accumulation of the drug after repeated dosing treatments is negligible. In patients with persistent asthma carmoterol 2 µg administered once daily is as effective as formoterol 12 µg twice daily. Safety and tolerability results are similar between carmoterol and formoterol. There were no significant changes in ECG results, blood pressure or serum potassium or glucose levels
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20402514 |
3.19 nM [Ki] |
Sample Use Guides
In Vivo Use Guide
Sources: Kanniess F, Make BJ, Petruzzelli S. Acute effect of carmoterol, a long-acting β2-agonist, in patients with COPD [abstract] Proc Am Thorac Soc. 2008;5:A655. https://www.ncbi.nlm.nih.gov/pubmed/21232045
4 µg of 2 µg
Route of Administration:
Respiratory
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:18:26 GMT 2025
by
admin
on
Mon Mar 31 18:18:26 GMT 2025
|
| Record UNII |
9810NUL4D1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB25400
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
147568-66-9
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL1094785
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
C171749
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
100000089411
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
63952
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
8404
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
Carmoterol
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
9810NUL4D1
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY | |||
|
DTXSID201046374
Created by
admin on Mon Mar 31 18:18:26 GMT 2025 , Edited by admin on Mon Mar 31 18:18:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |